Application of PDCD4 as a therapeutic target for antidepressants and/or anxiolytics drugs
US11320440B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 7, 2017 |
| Grant date | May 3, 2022 |
| Priority date | — |
| Expiry date | Jun 24, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/304
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application of PDCD4 as a drug treatment target for anti-depression and/or anti-anxiety disorders has been proved by experimental research that the increase of PDCD4 is an important factor leading to depression in the process of stress; PDCD4 as a target to inhibit its expression or function can play a good antidepressant role, and has no effect on normal physiological state. Therefore, PDCD4 can be used as a target in the preparation and screening of antidepressant and/or anxiolytic drugs, which has a broad application prospect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.